Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California
blank

 

Recent News and Articles on the Keywords: new therapy + new data + anastrozole  Related to the article below (Last Update: 5/12/2008)

New Data at ERA-EDTA Show Mimpara? (Cinacalcet) Improves ...
Business Wire (press release), CA - May 11, 2008
For the first time, these new final data demonstrate cinacalcet's effectiveness in daily clinical practice, confirming that improvements seen with ...
ALSO NOTED: FDA OKs Novalar therapy; StemCells files new patent ...
FierceBiotech, DC -
Report > Takeda and Affymax have posted more positive mid-stage data for their experimental anemia therapy. Release > Pipex Pharmaceuticals is reporting ...
ImClone Falls After Analyst Says Sell, Citing Data (Update1)
Bloomberg -
If successful, the results may help double sales of the drug, said Eric Schmidt, an analyst at Cowen & Co. in New York, in April. ...IMCL - MS
Thallion Receives Health Canada Approval to Initiate Phase II for ...
FOXBusiness -
As a novel Ras pathway inhibitor, TLN-4601 represents a potential new therapy for GBM patients. The animal data we released last fall, which demonstrated ...TSE:TLN - OTC:CMTX
Pollution and blood clots
Science News -
For the new analysis, Harvard?s Andrea Baccarelli and his colleagues tapped data that had been collected in the greater Milan area comparing people with DVT ...
Tercica Inc. Q1 2008 Earnings Call Transcript
Seeking Alpha, NY -
... we are pleased to note that in the weekly IMS exponent data averaged across the last four weeks, Somatuline Depot captured 8.2% of new prescription and ...
Tercica Reports First Quarter 2008 Financial Results Genetic Engineering News (press release)
all 2 news articles »  TRCA
Wireless Monitoring Network for Heart Patients
mediacaster, Canada -
Once a CareAlert has been received, physicians can review the new patient data and provide care by adjusting device or drug therapy as necessary. ...
Current Research Initiatives in Asthma
Medscape (subscription) -
These studies are recruiting new patients. The next study was the Best Add-On Therapy Giving Effective Response (BADGER) trial. [8] This study focused on ...
AVI BioPharma Publishes Preclinical Data Reducing Inflammation in ...
CNNMoney.com -
Splice switching oligonucleotides, are a new class of drugs used to modify alternative RNA splicing in order to induce therapeutically favorable splice ...AVII
GTx, Inc. Reports First Quarter 2008 Financial Results
WELT ONLINE, Germany -
"We plan to file the New Drug Application with FDA this summer and are preparing for a launch of toremifene 80 mg in 2009. We have initiated the process for ...GTXI
Source: Google News

… comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol … -
W Jonat, A Howell, C Blomqvist, W Eiermann, G … - European Journal of Cancer, 1996 - Elsevier
... Anastrozole is a new potent and highly selective non ... breast cancer who progressed
after prior tamoxifen therapy. ... Based on this data, anastrozole 1 mg should be ...

Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial … -
P Dombernowsky, I Smith, G Falkson, R Leonard, L … - Journal of Clinical Oncology, 1998 - jco.ascopubs.org
... Hortobagyi Are Anthracycline-Taxane Regimens the New Standard of ... Home page KI Pritchard
Endocrine Therapy of Advanced ... and Implications of the Existing Data Clin ...

… Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With … -
EP Winer, C Hudis, HJ Burstein, AC Wolff, KI … - Journal of Clinical Oncology, 2005 - jco.ascopubs.org
... Are There New Data to Prompt a Recommendation for an Aromatase Inhibitor As Initial
Adjuvant Therapy in Unselected ... A year later, updated data showed that the ...

Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced … -
J Bonneterre, A Buzdar, JMA Nabholtz, JFR … - Cancer, 2001 - doi.wiley.com
... other at 83 sites in Europe, Australia, New Zealand, South ... Anastrozole as First-Line
Therapy in Hormone Receptor Positive ... which was conducted on all data up to ...

… Comparing the Efficacy and Tolerability of Fulvestrant Versus Anastrozole in Postmenopausal Women … -
CK Osborne, J Pippen, SE Jones, LM Parker, M Ellis … - Journal of Clinical Oncology, 2002 - jco.ascopubs.org
... in this window] [in a new window], Fig 6 ... and progressive disease or to concomitant
therapy (eg, opiates ... prospectively protocoled for the combined data from this ...

Meeting Highlights: Updated International Expert Consensus on the Primary Therapy of Early Breast … -
A Goldhirsch, WC Wood, RD Gelber, AS Coates, B … - Journal of Clinical Oncology, 2003 - jco.ascopubs.org
... Evaluation of regional lymphnodes: New standards ... breast cancer treated with
breast-conserving therapy. ... partial breast irradiation: More data needed, researchers ...

… therapy in advanced breast cancer comparison of the aromatase inhibitors letrozole and anastrozole -
C Rose, O Vtoraya, A Pluzanska, N Davidson, M … - European Journal of Cancer, 2003 - Elsevier
... RD Rubens, Editor, Advanced Breast Cancer: Reassessing Hormonal Therapy, Parthenon,
New York (2000 ... update based on a combined analysis of data from two ...

Phase III Study of Letrozole Versus Tamoxifen as First-Line Therapy of Advanced Breast Cancer in … -
H Mouridsen, M Gershanovich, Y Sun, R Perez- … - Journal of Clinical Oncology, 2003 - jco.ascopubs.org
... D, et al: Letrozole, a new aromatase inhibitor ... versus tamoxifen as first-line therapy
for postmenopausal ... and Kolmogorov-Smirnov-type for randomly censored data. ...

Anastrozole Versus Tamoxifen as First-Line Therapy for Advanced Breast Cancer in 668 Postmenopausal … -
J Bonneterre, B Thurlimann, JFR Robertson, M … - Journal of Clinical Oncology, 2000 - jcojournal.org
... 603, 1991; Rose C, Mouridsen HT: Endocrine therapy of advanced ... based on a combined
analysis of data from two ... Falkson G, et al: Letrozole, a new oral aromatase ...

From Trousseau to targeted therapy: new insights and innovations in thrombosis and cancer -
MN Levine, AY Lee, AK Kakkar - Journal of Thrombosis and Haemostasis, 2003 - Blackwell Synergy
... Finally, based on preclinical data and meta-analyses, there ... 1997 symposium the potential
for anticoagulant therapy to reduce ... that has lead to much new research ...

Source: Google Scholar

New Data Show That 'Arimidex'® (Anastrozole) Is A Cost-Effective Therapy Compared To Tamoxifen

New data published this week in the British Journal of Cancer (BJC) confirms that 'Arimidex' (anastrozole) is a cost-effective treatment for early breast cancer, based on criteria established by the National Institute for Clinical Excellence (NICE) for commonly accepted cancer treatments. [1]

NICE concluded in November 2006 that Arimidex is cost-effective when compared with tamoxifen and therefore recommended it as an option for the adjuvant treatment of early oestrogen-receptor-positive invasive breast cancer in postmenopausal women.

These latest findings, based on the most recent methodology guidelines from NICE, further corroborates NICE's recommendations and adds to the growing evidence that 'Arimidex' offers a cost-effective alternative to tamoxifen in these patients.2, [3]

The annual cost of hormonal drug therapy to the NHS is estimated at £64.6 million. [4] However, drug acquisition costs do not reflect the total financial burden of breast cancer. Disease recurrence also has an adverse impact, significantly increasing the overall cost of treatment - specifically, in terms of diagnosis, clinic appointments, inpatient and outpatient care, the need for additional surgery/chemotherapy/radiotherapy, adverse event management for extra procedures and follow-up investigations.4, [5]

Professor Robert Mansel, University of Wales College of Medicine, Cardiff, UK, commented, "Recurrence is the single most important factor which increases total cost of breast cancer therapy. Therefore, reducing recurrence would have the largest influence on breast cancer spending. This model demonstrates that by prescribing a more effective treatment that reduces the risk of recurrence compared to tamoxifen, you can potentially reduce the overall economic burden on the healthcare system of treating breast cancer in this setting."

Historically, tamoxifen has been regarded as an effective and inexpensive treatment option for hormone-sensitive early breast cancer. However, results from the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trial have led to the increasing use of anastrozole in the initial adjuvant setting. The study demonstrated that anastrozole, an aromatase inhibitor (AI), is superior to tamoxifen in terms of reduced risk of recurrence and improved tolerability. [6], [7] This most recent publication supports the use of anastrozole as a cost-effective alternative to tamoxifen.1
The cost-effectiveness analysis published this week was conducted to evaluate the economic consequences of choosing anastrozole over tamoxifen in terms of costs, QALYs gained and cost per QALY gained based on a model estimated over a 25-year period. The validated Markov model revealed that:

-- Anastrozole lead to a gain in 0.244 QALYs (or 0.231 life years) at an additional cost of £4,315 per patient1

-- The estimated incremental cost-effectiveness of anastrozole compared to tamoxifen was £17,656 (95% CI:£10,280 TO £39,235) per QALY gained*1

-- The incremental cost per life year gained was £18,702.*1

Professor Lesley Fallowfield, Psychosocial Oncologist, Cancer Research, UK commented, "Results from ATAC showed that anastrozole offers post-menopausal women with hormone-sensitive breast cancer a greater chance of preventing recurrence. We have now provided evidence that this effective, well-tolerated treatment is also cost-effective which should be reassuring to budget-holders (or primary care trusts), doctors and women alike."

Anastrozole has an annual acquisition cost of £894.25 and is the least expensive AI available [8] - costing 17% less than letrozole and exemestane. In comparison, the annual cost of trastuzumab (Herceptin) and taxanes, such as paclitaxel, are significantly higher.

Anastrozole remains the first and only AI that has been extensively assessed for safety and efficacy for over five years as initial adjuvant treatment in postmenopausal breast cancer patients.

*The acceptability curve for this analysis demonstrates a > 90% probability that the cost per QALY gained with 'Arimidex' would be lower than the £30,000 threshold established by NICE for commonly used cancer treatments.1

References:

[1] R Mansel et al on behalf of the ATAC Trialists' Group. Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed analysis of ATAC ('Arimidex', Tamoxifen alone or in combination) trial. British Journal of Cancer (2007) 97: 152 - 161.

[2] NICE technology appraisal guidance 112 (Nov 1006)

[3] Hillner Be (2204) Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer. Cancer 101:1311 - 1322.

[4] Benedict A, Christie A (2003) Budget impact analysis of anastrozole as adjuvant therapy in the treatment of early breast cancer in the UK [abstract]. Value Health 6: 735.

[5] Lamerato L, Havstad S, Gandhi SK et al. Economic burden associated with breast cancer recurrence. Cancer 2006;106:1875-82

[6] ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005; 365 (9453):60-62.

[7] J Cuzick et al. A detailed analysis of the benefits of anastrozole over tamoxifen for venous thromboembolic events (VTEs) after 5 years' treatment. Abstract 104. San Antonia Breast Cancer Symposium 2006.

[8] emims, accessed at http://www.emims.net July 2007.

Quality Adjusted Life Year

A year of life adjusted for its quality or its value. A year in perfect health is considered equal to 1.0 QALY. The value of a year in ill health would be discounted. For example, a year bedridden might have a value equal to 0.5 QALY. QALYs can therefore provide an indication of the benefits gained from a variety of medical procedures in terms of quality and life and survival for the patient.

NICE

NICE guidance is developed by a number of independent advisory groups made up of health professionals, those working in the NHS, patients, their carers and the public. The Board and senior management team set the Institute's strategic direction and oversee delivery, provide financial stewardship and ensure corporate governance.

Markov Model

Markov models assume that a patient is always in one of a finite number of discrete health states and all events are represented as transitions from one state to another. In this study, the Markov model was evaluated as a Monte Carlo simulation. The model projected outcomes over an actuarial horizon of 25 years.

http://www.arimidex.com
 
 
Google
Web www.iconocast.com

Search inside Iconocast for the keyword you have in mind.

Iconocast has collected more than 50,000 articles and press releases on health and science.

These are current and most up to date press releases on the subject you are searching.

We collect current health and science press releases daily from more than 5000 research and health institutes. Here is an example : The elderberry way to perfect skin

We believe if you do search inside Iconocast, you will get better results than searching the web alone.

 
 
Continue News With: News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

Contact Iconocast

© 2003-07. ICONOCAST is a trademark of iconocast.com.